Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fl Liew

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Australian Prescriber|October 23, 2020
Real-time prescription monitoring: helping people at risk of harmMalcolm Dobbin, David Fl Liew
The Lancet. Rheumatology|January 22, 2024
Designing studies in newly diagnosed versus established polymyalgia rheumaticaDavid Fl Liew, Claire E Owen
The Lancet. Rheumatology|June 22, 2025
Polymyalgia rheumatica: killing them softlyDavid Fl Liew, Claire E Owen
Australian Prescriber|August 27, 2025
Choosing a nonsteroidal anti-inflammatory drug for painStephanie Hopkins, Victor Yang, David Fl Liew
Australian Prescriber|December 6, 2023
Medicines stewardshipElizabeth Su, David Fl Liew, Jane Donnelly, et al.
Journal for Immunotherapy of Cancer|September 16, 2021
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational studyPankti Reid, David Fl Liew, Rajshi Akruwala, et al.
Australian Prescriber|September 14, 2020
Immunosuppression for COVID-19: repurposing medicines in a pandemicSenthuran Shivakumar, Olivia C Smibert, Jason A Trubiano, et al.
RMD Open|February 24, 2022
Waiting for JAK inhibitor safety dataTue Wenzel Kragstrup, Bente Glintborg, Annemarie L Svensson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 5, 2025
Polymyalgia rheumatica patients presenting with atypical clinical features still exhibit characteristic <sup>18</sup>F-FDG PET/CT findingsEmily Martin, Christopher R McMaster, Aurora Mt Poon, et al.
The Medical Journal of Australia|June 25, 2025
Promoting resilience to weather-related and seasonal provocations to health in people with multimorbid heart disease: a prospective pragmatic, randomised trialSimon Stewart, Sheila K Patel, Terase F Lancefield, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Australian Prescriber|October 23, 2020
Real-time prescription monitoring: helping people at risk of harmMalcolm Dobbin, David Fl Liew
The Lancet. Rheumatology|January 22, 2024
Designing studies in newly diagnosed versus established polymyalgia rheumaticaDavid Fl Liew, Claire E Owen
The Lancet. Rheumatology|June 22, 2025
Polymyalgia rheumatica: killing them softlyDavid Fl Liew, Claire E Owen
Australian Prescriber|August 27, 2025
Choosing a nonsteroidal anti-inflammatory drug for painStephanie Hopkins, Victor Yang, David Fl Liew
Australian Prescriber|December 6, 2023
Medicines stewardshipElizabeth Su, David Fl Liew, Jane Donnelly, et al.
Journal for Immunotherapy of Cancer|September 16, 2021
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational studyPankti Reid, David Fl Liew, Rajshi Akruwala, et al.
Australian Prescriber|September 14, 2020
Immunosuppression for COVID-19: repurposing medicines in a pandemicSenthuran Shivakumar, Olivia C Smibert, Jason A Trubiano, et al.
RMD Open|February 24, 2022
Waiting for JAK inhibitor safety dataTue Wenzel Kragstrup, Bente Glintborg, Annemarie L Svensson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 5, 2025
Polymyalgia rheumatica patients presenting with atypical clinical features still exhibit characteristic <sup>18</sup>F-FDG PET/CT findingsEmily Martin, Christopher R McMaster, Aurora Mt Poon, et al.
The Medical Journal of Australia|June 25, 2025
Promoting resilience to weather-related and seasonal provocations to health in people with multimorbid heart disease: a prospective pragmatic, randomised trialSimon Stewart, Sheila K Patel, Terase F Lancefield, et al.
Pageof 2